1987 Volume 78 Issue 8 Pages 1403-1408
Prostatic acid phosphatase (PAP), γ-seminoprotein (γ-Sm) and prostatic specific antigen (PA) were determined by double antibody radioimmunoassay and enzyme immunoassay in 97 patients with prostatic cancer (the untreated: 35, the treated: 62), 316 with prostatic hypertrophy, 41 with bladder cancer and 138 with other benign urological diseases to assess the clinical usefulness as a tumor marker.
Positive rates of PAP, γ-Sm and PA levels were 74.3%, 73.1% and 79.4%, respectively, in patients with untreated prostatic cancer, while those were 2.8%, 12.5% and 12.3%, respectively, in patients with prostatic hypertrophy. Although the highest sensitivity was found in PA levels, the highest specificity was shown by PAP levels.
A slight correlation was found between PAP and PA, but no significant correlation was present with γ-Sm.
The positive rate in untreated prostatic cancer patients increased by the combination assay of these three markers, and moreover, different variations of these markers were noted with various therapies in prostaitc cancer patients. These data suggested that the combination assay of these markers was useful for diagnosis and monitoring of prostatic cancer patients.
